SCHEMBL6624772

SCHEMBL6624772

Cc1cc(Cl)cc(Cl)c1S(=O)(=O)Nc1ccsc1CCN1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.42
KDM4E B2RXH2 2/20 0.40
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
NMT1 P30419 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 2/20 0.37
HTR6 P50406 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6629251 0.93 HSD11B1 (0.47) HSD11B1KDM4EMAPTNPSR1ALDH1A1
SCHEMBL6624382 0.86 HSD11B1 (0.37) HSD11B1KDM4EMAPTNPSR1ALDH1A1
SCHEMBL6623700 0.83 CNR1 (0.44) KDM4EMAPTALDH1A1MAPK1NMT1
SCHEMBL6623740 0.83 HSD11B1 (0.55) HSD11B1KDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL6614389 0.82 HSD11B1 (0.42) HSD11B1KDM4EMAPTNPSR1ALDH1A1
SCHEMBL6627341 0.80 HSD11B1 (0.46) HSD11B1KDM4EALDH1A1MAPK1SMN1; SMN2
Hydrochloric Acid SCHEMBL3611528 0.79 HSD11B1 (0.60) HSD11B1KDM4EMAPTNPSR1ALDH1A1
SCHEMBL6624148 0.79 HSD11B1 (0.42) HSD11B1MAPTNMT1SMN1; SMN2KMT2A
SCHEMBL6687477 0.78 HSD11B1 (0.51) HSD11B1MAPTALDH1A1SMN1; SMN2KMT2A
SCHEMBL5830637 0.77 ALDH1A1 (0.46) HSD11B1KDM4EALDH1A1MAPK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885KDM4E 3105/4885MAPT 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.